It is trading at $103.85 barely below $111.44, the 50 day moving average and which is just under the 200 day moving average of $109.44. The 50 day moving average went down by -6.92% and the 200 day average went down $-5.71 or -5.22%. 124K shares changed hands on Wednesday. Shares saw a steep increase in trading volume of 0.45% over the normal average daily volume.
Investors are a little more bullish recently as implied by the change in short interest. The stock experienced a fall in short interest of -31.73% between June 15, 2017 and May 31, 2017. Short shares decreased 514,438 over that timeframe. Days to cover decreased -6.3 to 6.8 and the percentage of shorted shares was 0.04% on May 31.
Here is the rundown on market activity for China Biologic Products, Inc. (NASDAQ:CBPO). Gang Cbpo Yang, Corporate Vice President sold $1,044,288 worth of shares at an average price of $124.32 on August 15th. That brings Yang’s holdings to $4,008,325 as recorded in a recent Form 4 SEC filing. CFO Ming Yang disclosed the sale of 21,092 shares. The shares were sold on August 15th for an average price of $124.32. Yang now owns $3,080,898 of the stock per the Form 4 SEC filing.
Ming Yin, Sr. Corporate Vice President let go of $2,527,923 worth of shares at an average price of $124.32 on Mon the 15th. That brings the Sr. Corporate Vice President’s holdings to $2,047,177 per an SEC filing yesterday.
The following firms have also recently changed their position in CBPO. As of the end of the quarter Vontobel Asset Management Inc had disposed of 6,439 shares trimming its holdings by 11.2%. The value of the total investment in China Biologic Products, Inc. increased from $5,735,000 to $5,750,000 increasing 0.3% for the reporting period. As of quarter end Copper Rock Capital Partners, LLC had bought a total of 4,025 shares growing its position 13.0%. The value in dollars went from $3,086,000 to $3,893,000 a change of $807,000 since the last quarter.
As of quarter end Goldman Sachs Group Inc had bought 48,843 shares growing its stake by 502.7%. The value of the investment in China Biologic Products, Inc. went from $1,045,000 to $5,863,000 a change of 461.1% quarter to quarter. As of quarter end Macquarie Group Ltd had bought 47,697 shares growing its stake by 186.4%. The value of the investment in CBPO increased from $2,721,000 to $7,338,000 a change of 169.7% quarter over quarter.
On March 1 the company was downgraded from “Outperform” to “Neutral” in a statement from Credit Suisse. February 29 investment analysts at Jefferies held the stock rating at “Buy” but moved down the price target from $138.00 to $136.00.
On August 7 Jefferies kept the stock rating at “Buy” but raised the price target to $146.00 from $122.00. Bank of America starting coverage on the stock with a rating of “Buy” and price target of $135.00.
On November 6 Jefferies maintained a stock rating of “Buy” but raised the price expectation from $57.00 to $76.00. July 24 investment analysts at Jefferies left the stock rating at “Buy” and raised the price expectation from $52.00 to $57.00.
The company is now up from yesterday’s close of $103.73. China Biologic Products, Inc. currently has a P/E ratio of 26.87 and the market cap of the company is 2.82B. As of the last earnings report the EPS was $3.86 and is estimated to be $5.05 for the current year with 27,201,000 shares presently outstanding. Analysts expect next quarter’s EPS to be $1.24 with next year’s EPS projected to be $5.81.
China Biologic Products, Inc. (China Biologic), launched on January 10, 2007, is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories..